Status: Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 40 and 48.
Participants needed: 332
Trial details
Phase: Phase 3Age: 50-80Biological sex: AllType: InterventionalSponsor: Innostellar Biotherapeutics Co.,LtdUpdated: Mar 5, 2026Locations: 31
Eligibility criteria
Willing and able to provide written, signed informed consent for this study; [+6]
Any condition in the investigator's opinion that could limit VA improvement in t... [+9]